|
Oncogenes and Tumor Suppressors
Citations 331-340 of 795 total displayed.
|
Past content
(since May 2000):
|
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
- Deborah White, Verity Saunders, A. Bruce Lyons, Susan Branford, Andrew Grigg, L. Bik To, and Timothy Hughes
Blood 2005; 106: 2520-2526.
[Abstract]
[Full text]
[PDF]
Oncogenes as molecular targets in lymphoma
- Ali Hachem and Ronald B. Gartenhaus
Blood 2005; 106: 1911-1923.
[Full text]
[PDF]
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
- David T. Bowen, Marion E. Frew, Robert Hills, Rosemary E. Gale, Keith Wheatley, Michael J. Groves, Stephen E. Langabeer, Panagiotis D. Kottaridis, Anthony V. Moorman, Alan K. Burnett, and David C. Linch
Blood 2005; 106: 2113-2119.
[Abstract]
[Full text]
[PDF]
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy
- Stephanie G. Willis, Thoralf Lange, Shadmehr Demehri, Sandra Otto, Lucy Crossman, Dietger Niederwieser, Eric P. Stoffregen, Shannon McWeeney, Ines Kovacs, Byung Park, Brian J. Druker, and Michael W. Deininger
Blood 2005; 106: 2128-2137.
[Abstract]
[Full text]
[PDF]
Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos
- Kazuhiro Maki, Tetsuya Yamagata, Takashi Asai, Ieharu Yamazaki, Hideaki Oda, Hisamaru Hirai, and Kinuko Mitani
Blood 2005; 106: 2147-2155.
[Abstract]
[Full text]
[PDF]
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
- Amy V. Jones, Sebastian Kreil, Katerina Zoi, Katherine Waghorn, Claire Curtis, Lingyan Zhang, Joannah Score, Rachel Seear, Andrew J. Chase, Francis H. Grand, Helen White, Christine Zoi, Dimitris Loukopoulos, Evangelos Terpos, Elisavet-Christine Vervessou, Beate Schultheis, Michael Emig, Thomas Ernst, Eva Lengfelder, Rüdiger Hehlmann, Andreas Hochhaus, David Oscier, Richard T. Silver, Andreas Reiter, and Nicholas C. P. Cross
Blood 2005; 106: 2162-2168.
[Abstract]
[Full text]
[PDF]
Activation of  -diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase
- Roberta Bacchiocchi, Gianluca Baldanzi, Damiano Carbonari, Catia Capomagi, Emanuela Colombo, Wim J. van Blitterswijk, Andrea Graziani, and Francesca Fazioli
Blood 2005; 106: 2175-2182.
[Abstract]
[Full text]
[PDF]
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
- Christian P. Kratz, Charlotte M. Niemeyer, Robert P. Castleberry, Mualla Cetin, Eva Bergsträsser, Peter D. Emanuel, Henrik Hasle, Gabriela Kardos, Cornelia Klein, Seiji Kojima, Jan Stary, Monika Trebo, Marco Zecca, Bruce D. Gelb, Marco Tartaglia, and Mignon L. Loh
Blood 2005; 106: 2183-2185.
[Abstract]
[Full text]
[PDF]
Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression
- Erwan Le Scolan, Dimitri Pchejetski, Yoshiko Banno, Nicole Denis, Patrick Mayeux, William Vainchenker, Thierry Levade, and Françoise Moreau-Gachelin
Blood 2005; 106: 1808-1816.
[Abstract]
[Full text]
[PDF]
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
- Jeremy S. Abramson and Margaret A. Shipp
Blood 2005; 106: 1164-1174.
[Abstract]
[Full text]
[PDF]
|
|
